Bouras and colleagues attempted to use the cortisol total/CRP ratio for the prediction of hospital-acquired pneumonia (HAP) and initiation of corticosteroid therapy in patients with severe traumatic brain injury (TBI) and with adrenal insufficiency [1]. They found that a cortisol total/CRP ratio > 3 upon admission may predict the development of HAP in patients with severe TBI [1]. The study is interesting, while we have some concerns about the study design and interpretation of the data.
The CORTI-TC trial [2] revealed that low-dose hydrocortisone with fludrocortisone did not improve the outcome of patients with TBI. Although the relatively small sample size is considered as a reason for negative findings, we believe that stratified analyses are more important for such a study. HAP is a form of nosocomial pneumonia, which is distinct from VAP [3]. In a published guideline from the Infectious Diseases Society of America and the American Thoracic Society, the term HAP denotes an episode of pneumonia not associated with mechanical ventilation [4, 5]. As acknowledged also by the authors, mechanical ventilation promotes a specific histological pattern of pneumonia [1]. Hence, patients with HAP and ventilator-associated pneumonia (VAP) should be categorized into two distinct groups. All cases of recorded HAP were VAP [1], which means all these patients received mechanical ventilation. Thus, we are eager to know about the patients without HAP. What is the percentage of mechanical ventilation use in these patients?
In this post hoc analysis of the CORTI-TC trial, the authors may hypothesize that the cortisol total/CRP ratio may or may not predict HAP. However, HAP is more associated with disease severity per se, e.g., consciousness state, prophylactic use of antibiotics, duration of intensive care, and mechanical ventilation, with many comorbidities potentially acting as confounding factors. We are then interested to know about the prophylactic use of antibiotics in the CORTI-TC trial.
Seemingly, results from Table 1 and Table 2 are conflicting [1]. Whereas in Table 1, up to 20% patients without HAP (versus 5.6% in those without HAP) had body temperature > 39.0 °C upon admission, in Table 2, multivariate analysis revealed that body temperature > 39.0 °C was closely associated with HAP [1]. Besides, the unit of the leucocyte count in Table 1 is grams per liter, which should be typographical errors.
In summary, HAP is common after TBI and closely associated with its outcome. More studies are warranted to seek surrogate biomarkers to predict the occurrence of HAP.
Acknowledgements
None.
Authors’ contributions
LJ and HZ conceived the topic. LJ drafted the manuscript. HZ critically revised the manuscript. Both authors read and approved the final manuscript.
Authors’ information
Nil.
Funding
None.
Availability of data and materials
Not applicable.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Both authors approved the final version for submission and publication.
Competing interests
The authors declare that they have no competing interests.
Footnotes
This comment refers to the article available at 10.1186/s13054-019-2680-6.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Linpei Jia, Email: anny_069@163.com.
Hongliang Zhang, Email: drzhl@hotmail.com.
References
- 1.Bouras M, Roquilly A, Mahé PJ, et al. Cortisol total/CRP ratio for the prediction of hospital-acquired pneumonia and initiation of corticosteroid therapy in traumatic brain-injured patients. Crit Care. 2019;23:394. doi: 10.1186/s13054-019-2680-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Asehnoune K, Seguin P, Allary J, et al. Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trial. Lancet Respir Med. 2014;2:706–716. doi: 10.1016/S2213-2600(14)70144-4. [DOI] [PubMed] [Google Scholar]
- 3.Niederman MS. Antibiotic treatment of hospital-acquired pneumonia: is it different from ventilator-associated pneumonia? Curr Opin Crit Care. 2018;24:353–360. doi: 10.1097/MCC.0000000000000531. [DOI] [PubMed] [Google Scholar]
- 4.Kalil AC, Metersky ML, Klompas M, et al. Executive summary: management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:575–582. doi: 10.1093/cid/ciw504. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61–e111. doi: 10.1093/cid/ciw353. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Not applicable.